This year on EHA, we shared exciting new data on Imbruvica
(ibrutinib) in RESONATE-2
Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.
Categories / tags
See all related
Ghia P, et al. Up to 7 years of follow-up in the RESONATE-2 study of first-line ibrutinib for patients with chronic lymphocytic leukemia. Poster presented at: 26th congress of EHA; 9-12 June 2021; virtual meeting.
CP-240988 - June 2021
Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.